Over the last few decades, immunotherapy has developed at a rapid rate in the treatment of cancer where neoantigens are the latest breakthrough in tumour immunotherapy. Today, it is still unclear when a cancer vaccine will be made commercially available; what is the latest academic research showing us? What is the industry missing and where are we going?

Join us through a series of inspiring keynote presentations and engaging panel discussions to connect with top pioneers in the space, to discuss the future of cancer immunotherapy and how neoantigens are transforming the field.

Unlock the new era of vaccine development at Cancer Neoantigen Vaccines, a 1-day digital conference taking place February 2, 2023 and discover the path to commercial success with novel approaches toward cancer neoantigen vaccines.

You’ll shape the future of next generation cancer vaccine development with new oncolytic approaches and critical immunotherapy strategies and uncover, key research on targets and evolution, how to successfully enter global markets and the future of personalisation and beyond.

You can expect to uncover methods of identifying true targets and deep dive into the future of machine and deep learning in identifying neoantigens. Plus, you’ll hear successful case studies and promising data on the latest neoantigen vaccine development and gain a deeper understanding of the future of vaccines in personalised medicine. Don’t miss your opportunity to be a part of the discussions with industry experts on their look to the future.

All of this plus much more without leaving your desk! Your digital pass gives you access to the full attendee list with video chat, instant message, and meeting request functionalities to connect with like-minded thought-leaders in the field to expand your network, and access to the content on-demand for 10 working days post-event.